Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enteric-coated mycophenolate sodium.

Steven Gabardi1, Jennifer L Tran, Michael R Clarkson

  • 1Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA 02115-6110, USA. sgabardi@partners.org

The Annals of Pharmacotherapy
|October 21, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune Checkpoint Inhibitor Use in Kidney Transplant Patients: A National Case Series From Ireland.

Clinical transplantation·2025
Same author

Potential Effects of Remdesivir on Tacrolimus Exposure in Transplant Recipients With COVID-19 Infection.

Kidney international reports·2023
Same author

ANCA-associated vasculitis in Ireland: a multi-centre national cohort study.

HRB open research·2023
Same author

A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation.

Transplantation·2022
Same author

Immunosuppression in the Age of Precision Medicine.

Seminars in nephrology·2022
Same author

Primary Caregiver Retention and Perceptions of Retention Strategies in a 36-Month Prospective Childhood Caries Study.

Journal of primary care & community health·2022
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Mycophenolate sodium effectively prevents kidney transplant rejection, showing similar efficacy and safety to mycophenolate mofetil. This prodrug offers a potential alternative for reducing gastrointestinal side effects in transplant patients.

Area of Science:

  • Immunopharmacology
  • Transplantation Medicine

Background:

  • Mycophenolate mofetil is a widely used immunosuppressant.
  • Gastrointestinal adverse events are a concern with mycophenolate mofetil.
  • Mycophenolate sodium is a prodrug of mycophenolic acid.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, efficacy, and safety of mycophenolate sodium.
  • To compare mycophenolate sodium with mycophenolate mofetil in solid organ transplantation.

Main Methods:

  • MEDLINE literature search (1966-June 2003).
  • Inclusion of English-language human studies and manufacturer abstracts.
  • Analysis of studies evaluating mycophenolate sodium in solid organ transplantation.

Main Results:

Related Experiment Videos

  • Mycophenolate sodium inhibits T-lymphocyte proliferation and reduces acute rejection in renal transplantation.
  • Enteric coating of mycophenolate sodium may reduce gastrointestinal adverse events.
  • Mycophenolate sodium and mycophenolate mofetil demonstrate therapeutic equivalence in preventing allograft rejection and loss.
  • Adverse event profiles are similar, with diarrhea and leukopenia being most common.

Conclusions:

  • Mycophenolate sodium is effective in preventing acute rejection in renal transplant recipients.
  • At 720 mg twice daily, mycophenolate sodium has comparable efficacy and safety to mycophenolate mofetil at 1000 mg twice daily.
  • Mycophenolate sodium is approved in Switzerland, with US approval pending.